Relmada Therapeutics (RLMD) stock price is $3.37, up 0.15% on the day, as of Oct 21, 2026. It has a market cap of $379.27Mn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap379.27 Mn
P/E-6.12
Div. Yield0.00
Add ratio to table…
About
Relmada Therapeutics, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing novel therapeutics for cancer and neurological disorders. The company leverages its drug development expertise and clinical operations capabilities to advance product candidates that address high unmet medical need. Its current pipeline centers on two programs: NDV-01 for non-muscle-invasive bladder cancer and sepranolone for neuropsychiatric conditions.
Relmada…
Relmada Therapeutics, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing novel therapeutics for cancer and neurological disorders. The company leverages its drug development expertise and clinical operations capabilities to advance product candidates that address high unmet medical need. Its current pipeline centers on two programs: NDV-01 for non-muscle-invasive bladder cancer and sepranolone for neuropsychiatric conditions.
Relmada Therapeutics, Inc. does not generate revenue at present because none of its product candidates have received regulatory approval for commercial sale. The company anticipates future revenue from the sale of approved products, milestone payments under licensing agreements, and royalties on net sales. Until approval is achieved, the company funds its operations through equity offerings, debt financing, and strategic partnerships.
The company operates through the following segments:
NDV-01: This segment focuses on the development of a controlled-release intravesical formulation of gemcitabine and docetaxel for the treatment of non-muscle-invasive bladder cancer, aiming to provide sustained drug exposure with reduced systemic toxicity.
Sepranolone: This segment focuses on the development of a neurosteroid epimer of allopregnanolone for potential treatment of Prader-Willi syndrome, Tourette syndrome, essential tremor and other disorders linked to excessive GABAergic activity, seeking to normalize GABA A receptor activity without direct interference with GABA signaling.
Relmada Therapeutics, Inc. positions itself as a specialized biotechnology firm with a strong intellectual property portfolio and experienced management team, competing against larger pharmaceutical companies that possess greater financial and marketing resources. Its competitive advantages include extensive patent coverage for both NDV-01 and sepranolone, a deep understanding of clinical development pathways, and strategic alignments with regulatory agencies such as the FDA to facilitate efficient trial designs.
Relmada Therapeutics, Inc. currently serves no customers because it has no approved products on the market. Upon successful commercialization, the company expects to serve hospitals, urology clinics, oncology centers, neurology practices and patients seeking treatment for bladder cancer or neuropsychiatric disorders.
Sector:HealthcareSector rationaleRelmada Therapeutics is a clinical-stage biotechnology company developing therapeutics for cancer (NDV-01) and neurological disorders (sepranolone). Its business model is centered on the discovery and development of medical products, which falls squarely within the Biotechnology and Pharmaceuticals industries of the Healthcare sector.Industry:BiotechnologyBiotechnologyPrimaryRelmada Therapeutics is a clinical-stage biotechnology company developing therapies such as sepranolone, a neurosteroid epimer, and NDV-01. The company's business model is based on biology-based drug discovery and development, with anticipated future revenue from product sales, milestones, and royalties.Classified using BQ-MICSCIK: 0001553643
Bull & bear
Investment Thesis
▲ Bull case
The market is underestimating the durability and depth of NDV01's clinical response in BCG-unresponsive NMIBC, where a 94% complete response rate at any time in Phase II—driven by a sustained-release formulation enabling high local drug exposure—significantly outperforms historical benchmarks like Keytruda (19% 12-month CR) and valrubicin (8%). This level of efficacy, combined with zero progression to muscle-invasive disease and no grade 3+ adverse events in the 12-month dataset, positions NDV01 as a potential paradigm shift for a patient population with limited bladder-sparing options, where radical cystectomy remains the standard despite significant morbidity. The FDA's lack of mandated minimum follow-up for NDA submission in the BCG-unresponsive pathway, coupled with the agency's emphasis on "totality of data" including durability, reduces regulatory risk and accelerates the path to approval, especially as interim three-month data from the RESCUE program is expected by year-end 2026—providing an early catalyst that could de-risk investment ahead of full trial completion.
Relmada's financing strategy has created a de-risked operational runway extending through 2029, far beyond the anticipated completion of the Phase III RESCUE program, with $93 million in year-end cash bolstered by a $160 million private financing and $94 million from an underwritten offering. This financial strength eliminates near-term dilution concerns and allows the company to execute its dual-pathway Phase III strategy without financial strain, enabling investment in site activation (targeting 80 North American sites) and patient enrollment—critical advantages in a competitive landscape where trials like CG Oncology's intermediate-risk study have struggled with slow accrual. The in-office, sub-five-minute administration of NDV01 offers a tangible recruitment and retention edge over burdensome intravenous or surgical alternatives, directly addressing investigator concerns about enrollment cadence and making real-world adoption more feasible post-approval, particularly in community urology settings where convenience drives prescribing behavior.
The sopranolone program represents a hidden diversification catalyst that the market is overlooking, with a planned mid-2026 proof-of-concept Phase II trial in Prader-Willi syndrome targeting a GABA-modulating mechanism with precedent in Tourette syndrome. While currently preclinical in this indication, the program leverages Relmada's existing expertise in GABAergic modulation and benefits from low-cost, efficient trial design in a rare disease space with high unmet need and potential for orphan drug designation—offering a low-cost, high-optionality pipeline extension that could de-risk reliance on NDV01 alone and attract strategic interest from larger CNS-focused players, especially as data readouts begin in late 2026.
The market is underestimating the durability and depth of NDV01's clinical response in BCG-unresponsive NMIBC, where a 94% complete response rate at any time in Phase II—driven by a sustained-release formulation enabling high local drug exposure—significantly outperforms historical benchmarks like Keytruda (19% 12-month CR) and valrubicin (8%). This level of efficacy, combined with zero progression to muscle-invasive disease and no grade 3+ adverse events in the 12-month dataset, positions NDV01 as a potential paradigm shift for a patient population with limited bladder-sparing options, where radical cystectomy remains the standard despite significant morbidity. The FDA's lack of mandated minimum follow-up for NDA submission in the BCG-unresponsive pathway, coupled with the agency's emphasis on "totality of data" including durability, reduces regulatory risk and accelerates the path to approval, especially as interim three-month data from the RESCUE program is expected by year-end 2026—providing an early catalyst that could de-risk investment ahead of full trial completion.
Relmada's financing strategy has created a de-risked operational runway extending through 2029, far beyond the anticipated completion of the Phase III RESCUE program, with $93 million in year-end cash bolstered by a $160 million private financing and $94 million from an underwritten offering. This financial strength eliminates near-term dilution concerns and allows the company to execute its dual-pathway Phase III strategy without financial strain, enabling investment in site activation (targeting 80 North American sites) and patient enrollment—critical advantages in a competitive landscape where trials like CG Oncology's intermediate-risk study have struggled with slow accrual. The in-office, sub-five-minute administration of NDV01 offers a tangible recruitment and retention edge over burdensome intravenous or surgical alternatives, directly addressing investigator concerns about enrollment cadence and making real-world adoption more feasible post-approval, particularly in community urology settings where convenience drives prescribing behavior.
The sopranolone program represents a hidden diversification catalyst that the market is overlooking, with a planned mid-2026 proof-of-concept Phase II trial in Prader-Willi syndrome targeting a GABA-modulating mechanism with precedent in Tourette syndrome. While currently preclinical in this indication, the program leverages Relmada's existing expertise in GABAergic modulation and benefits from low-cost, efficient trial design in a rare disease space with high unmet need and potential for orphan drug designation—offering a low-cost, high-optionality pipeline extension that could de-risk reliance on NDV01 alone and attract strategic interest from larger CNS-focused players, especially as data readouts begin in late 2026.
Relmada is overstating the addressable market for its intermediate-risk bladder cancer pathway by assuming 75,000 annual U.S. patients will be eligible for adjuvant NDV01 therapy post-TURBT, when real-world adoption data shows only ~35% of this population currently receives any adjuvant treatment due to lack of approved agents, reimbursement challenges in the buy-and-bill model, and physician hesitation to overtreat low-risk Ta lesions—meaning the actual treatable population may be closer to 26,000 patients annually, significantly reducing peak sales potential and undermining the financial models that underpin the current valuation.
The company's reliance on a single-arm, open-label design for the BCG-unresponsive Phase III RESCUE pathway introduces substantial regulatory and perceptual risk, as the FDA, while not mandating minimum follow-up, emphasized the need to see "durability of response" and "totality of data"—a subjective standard that could invite scrutiny if long-term relapse rates emerge post-approval, especially given that historical monotherapies in this space (e.g., Keytruda) show declining response rates beyond 12 months, and without a control arm, it will be difficult to distinguish drug effect from natural history or placebo response in a population where spontaneous remission, though rare, has been documented.
Sopranolone's advancement into a Prader-Willi syndrome proof-of-concept study is premature and potentially distracting, as the program lacks mechanistic validation in this specific indication beyond Tourette syndrome data, and the GABA-modulating steroid antagonist class has yet to demonstrate consistent efficacy across compulsivity disorders—diverting limited R&D and operational focus from the critical NDV01 Phase III launch at a time when execution risk is highest, with general and administrative expenses already rising 4.2% year-over-year in Q4 2025 due to compensation increases, signaling potential inefficiency in scaling operations before pivotal trial data is secured.
Relmada is overstating the addressable market for its intermediate-risk bladder cancer pathway by assuming 75,000 annual U.S. patients will be eligible for adjuvant NDV01 therapy post-TURBT, when real-world adoption data shows only ~35% of this population currently receives any adjuvant treatment due to lack of approved agents, reimbursement challenges in the buy-and-bill model, and physician hesitation to overtreat low-risk Ta lesions—meaning the actual treatable population may be closer to 26,000 patients annually, significantly reducing peak sales potential and undermining the financial models that underpin the current valuation.
The company's reliance on a single-arm, open-label design for the BCG-unresponsive Phase III RESCUE pathway introduces substantial regulatory and perceptual risk, as the FDA, while not mandating minimum follow-up, emphasized the need to see "durability of response" and "totality of data"—a subjective standard that could invite scrutiny if long-term relapse rates emerge post-approval, especially given that historical monotherapies in this space (e.g., Keytruda) show declining response rates beyond 12 months, and without a control arm, it will be difficult to distinguish drug effect from natural history or placebo response in a population where spontaneous remission, though rare, has been documented.
Sopranolone's advancement into a Prader-Willi syndrome proof-of-concept study is premature and potentially distracting, as the program lacks mechanistic validation in this specific indication beyond Tourette syndrome data, and the GABA-modulating steroid antagonist class has yet to demonstrate consistent efficacy across compulsivity disorders—diverting limited R&D and operational focus from the critical NDV01 Phase III launch at a time when execution risk is highest, with general and administrative expenses already rising 4.2% year-over-year in Q4 2025 due to compensation increases, signaling potential inefficiency in scaling operations before pivotal trial data is secured.